Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel: +47 21 07 81 60
E-mail:

Copyright/Disclaimer

List of DDDs for 3 years revision

The DDDs, which will be reviewed at the March 2024 meeting (3 year revision) are listed below. See also Guidelines: Part III; D Principles for reviewing and changing DDD and Part V; D Requests for changes to DDDs. The deadline for applications for alterations and comments is 1 February 2024.

ATC code	ATC level name (INN/generic name)	DDD	Unit	Adm.route


A03FA07	itopride	0.15	g	O
A10BJ06	semaglutide	10.5	mg	O
A16AB15	velmanase alfa	10	mg	P
B02BX08	avatrombopag	20	mg	O
B03XA06	luspatercept	3.33	mg	P
B06AX01	crizanlizumab	12.5	mg	P
C08EX02	perhexiline	0.2	g	O
C10AX06	omega-3-triglycerides incl. other esters and acids	4	g	O
H02CA03	ketoconazole	0.6	g	O
J01MA15	gemifloxacin	0.2	g	P
J05AB16	remdesivir	0.1	g	P
J05AG05	rilpivirine	15	mg	P
J05AH01	zanamivir	1.2	g	P
J05AJ04	cabotegravir	10	mg	P
J05AJ04	cabotegravir	30	mg	O
J05AX29	fostemsavir	1.2	g	O
L01EA01	imatinib	0.4	g	O
L01EA02	dasatinib	0.1	g	O
L01EA03	nilotinib	0.6	g	O
L01EA04	bosutinib	0.4	g	O
L01EA05	ponatinib	45	mg	O
L01EB01	gefitinib	0.25	g	O
L01EB02	erlotinib	0.15	g	O
L01EB03	afatinib	40	mg	O
L01EB04	osimertinib	80	mg	O
L01EB07	dacomitinib	45	mg	O
L01EC01	vemurafenib	1.92	g	O
L01EC02	dabrafenib	0.3	g	O
L01EC03	encorafenib	0.45	g	O
L01ED01	crizotinib	0.5	g	O
L01ED02	ceritinib	0.45	g	O
L01ED03	alectinib	1.2	g	O
L01ED04	brigatinib	0.18	g	O
L01ED05	lorlatinib	0.1	g	O
L01EE01	trametinib	2	mg	O
L01EE02	cobimetinib	45	mg	O
L01EE03	binimetinib	90	mg	O
L01EF01	palbociclib	94	mg	O
L01EF02	ribociclib	0.45	g	O
L01EF03	abemaciclib	0.3	g	O
L01EG01	temsirolimus	3.57	mg	P
L01EG02	everolimus	10	mg	O
L01EH01	lapatinib	1.25	g	O
L01EH02	neratinib	0.24	g	O
L01EH03	tucatinib	0.6	g	O
L01EJ01	ruxolitinib	30	mg	O
L01EJ02	fedratinib	0.4	g	O
L01EK01	axitinib	10	mg	O
L01EK03	tivozanib	1	mg	O
L01EL01	ibrutinib	0.42	g	O
L01EL02	acalabrutinib	0.2	g	O
L01EL03	zanubrutinib	0.32	g	O
L01EM01	idelalisib	0.3	g	O
L01EM02	copanlisib	6.43	mg	P
L01EM03	alpelisib	0.3	g	O
L01EM04	duvelisib	50	mg	O
L01EN01	erdafitinib	9	mg	O
L01EN02	pemigatinib	9	mg	O
L01EX01	sunitinib	33	mg	O
L01EX02	sorafenib	0.8	g	O
L01EX03	pazopanib	0.8	g	O
L01EX04	vandetanib	0.3	g	O
L01EX05	regorafenib	0.12	g	O
L01EX07	cabozantinib	60	mg	O
L01EX08	lenvatinib	18	mg	O
L01EX09	nintedanib	0.38	g	O
L01EX10	midostaurin	0.1	g	O
L01EX12	larotrectinib	0.2	g	O
L01EX13	gilteritinib	0.12	g	O
L01EX14	entrectinib	0.6	g	O
L01EX15	pexidartinib	0.8	g	O
L01EX17	capmatinib	0.8	g	O
L01EX18	avapritinib	0.3	g	O
L01EX19	ripretinib	0.15	g	O
L01EX22	selpercatinib	0.32	g	O
L01EX23	pralsetinib	0.4	g	O
L02BB06	darolutamide	1.2	g	O
L04AA38	ozanimod	0.92	mg	O
L04AA41	imlifidase	17.5 ¹⁾	mg	P
L04AA43	ravulizumab	58.9	mg	P
L04AA44	upadacitinib	15	mg	O
N02BG11	mirogabalin	25	mg	O
N03AX24	cannabidiol	0.7	g	O
N05AL05	amisulpride	7.5	mg	P
N05CF04	eszopiclone	2	mg	O
N06AX27	esketamine	8	mg	N
N06AX28	levomilnacipran	40	mg	O
R03CC15	formoterol	0.16	mg	O
V03AG05	sodium phosphate	8	g	O

1) course dose

Last updated: 2024-01-26